1 January – 30 June (unaudited)
|
kEUR |
H1 2026 |
H1 2025 |
|
|
|
|
|
|
|
Revenue |
236,628 |
167,096 |
|
|
Other operating income |
10,272 |
503 |
|
|
Total income |
|
246,900 |
167,599 |
|
|
|
|
|
|
Cost of sales |
|
-183,214 |
-153,308 |
|
Gross profit / (loss) |
|
63,686 |
14,291 |
|
|
|
|
|
|
Marketing and sales expenses |
|
-2,164 |
-2,120 |
|
Research expenses |
|
-1,560 |
-909 |
|
General and administrative expenses |
-37,983 |
-24,985 |
|
|
Total operating expenses |
|
-41,707 |
-28,014 |
|
|
|
|
|
|
Operating result (EBIT) |
|
21,979 |
-13,723 |
|
|
|
|
|
|
Financial income |
|
3,416 |
492 |
|
Financial expenses |
|
-11,235 |
-17,823 |
|
Total financial result |
|
-7,819 |
-17,331 |
|
|
|
|
|
|
Result before income taxes |
|
14,160 |
-31,054 |
|
|
|
|
|
|
Income tax |
|
-5,079 |
4,515 |
|
Result for the period |
|
9,081 |
-26,539 |
|
|
|
|
|
|
Attributable to shareholders of PolyPeptide Group AG |
|
9,081 |
-26,539 |
|
|
|
|
|
|
Earnings per share in EUR, basic |
|
0.28 |
-0.80 |
|
Earnings per share in EUR, diluted |
|
0.28 |
-0.80 |